14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management
Key Takeaways
- Alcohol-associated liver disease progresses through steatosis, which is reversible within weeks of abstinence, to steatohepatitis, fibrosis and cirrhosis.
- An AST to ALT ratio greater than 2 with both values usually below 300 to 400 IU/L is the classic biochemical signature of alcohol-associated hepatitis.
- A Maddrey discriminant function of 32 or higher identifies severe alcohol-associated hepatitis with high short-term mortality and is the historical threshold for considering corticosteroids.
- The Lille score at day 7 determines whether corticosteroids are working; a score of 0.45 or higher indicates non-response and supports stopping steroids.
- Naltrexone and acamprosate can both be used in compensated liver disease, but acamprosate is preferred when hepatic function is significantly impaired because it is cleared entirely by the kidneys.
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management
Quick Answer: Alcohol-associated liver disease (ALD) runs steatosis → steatohepatitis → fibrosis → cirrhosis. Steatosis reverses within 4 to 6 weeks of abstinence. Alcohol-associated hepatitis shows AST:ALT greater than 2 with values usually below 300 to 400 IU/L, plus bilirubin elevation and neutrophilia. Severity is graded with the Maddrey discriminant function (32 or higher = severe) and MELD; the Lille score at day 7 (0.45 or higher = non-response) decides whether to continue corticosteroids. Abstinence is the only therapy that changes long-term survival, which makes alcohol use disorder treatment a hepatology intervention.
1. The Spectrum
| Stage | Pathology | Reversibility | Typical findings |
|---|---|---|---|
| Steatosis | Macrovesicular fat accumulation | Fully reversible in 4 to 6 weeks of abstinence | Often asymptomatic; mild transaminase elevation; hepatomegaly |
| Alcohol-associated steatohepatitis | Ballooning degeneration, Mallory-Denk bodies, neutrophilic infiltrate | Partially reversible | Jaundice, tender hepatomegaly, fever, leukocytosis |
| Fibrosis | Pericellular and perivenular collagen deposition | Partially reversible early | Elevated FIB-4; increased liver stiffness on elastography |
| Cirrhosis | Regenerative nodules, architectural distortion | Not reversible, but decompensation can regress with abstinence | Ascites, varices, encephalopathy, coagulopathy, thrombocytopenia |
Only a minority of people with heavy alcohol use develop cirrhosis. Risk multipliers the APRN should assess and teach: female sex (greater injury per gram of alcohol), obesity and metabolic dysfunction, hepatitis C or B coinfection, daily rather than episodic drinking, drinking outside meals, and genetic variants such as PNPLA3.
2. Interpreting the Laboratory Pattern
- AST:ALT greater than 2 is the signature. It arises because alcohol depletes pyridoxal 5'-phosphate, which ALT synthesis requires more than AST, and because alcohol injures mitochondria, releasing mitochondrial AST.
- Magnitude matters. In alcohol-associated hepatitis, AST rarely exceeds 300 to 400 IU/L. Transaminases above 1,000 IU/L point to acetaminophen toxicity, ischemic hepatitis or acute viral hepatitis — an important distinction because a patient who drinks heavily may have all three risks at once.
- GGT is sensitive for heavy drinking but has poor specificity; it rises with metabolic liver disease, enzyme-inducing drugs and biliary disease.
- Phosphatidylethanol (PEth) is a direct alcohol biomarker with a detection window of roughly 2 to 4 weeks, substantially more specific than GGT or carbohydrate-deficient transferrin, and increasingly used in transplant evaluation.
- Platelet count falling below 150,000 in a heavy drinker is an early clue to portal hypertension.
3. Severity Scoring
| Score | Inputs | Threshold | Use |
|---|---|---|---|
| Maddrey discriminant function | Prothrombin time and total bilirubin | 32 or higher = severe | Historical trigger for considering corticosteroids |
| MELD / MELD 3.0 | Bilirubin, INR, creatinine, sodium (plus albumin and sex in MELD 3.0) | Higher scores predict short-term mortality; used for transplant allocation | Prognosis and listing |
| Lille score | Age, albumin, bilirubin at day 0 and day 7, creatinine, prothrombin time | 0.45 or higher = non-response | Decide whether to stop corticosteroids at day 7 |
| Glasgow alcoholic hepatitis score | Age, white cell count, urea, INR, bilirubin | 9 or higher identifies severe disease | Alternative severity index |
Corticosteroids (prednisolone 40 mg daily for 28 days) may be considered in severe alcohol-associated hepatitis without contraindication. They improve short-term but not long-term survival, and are withheld in active infection, gastrointestinal bleeding, and untreated hepatorenal syndrome. Pentoxifylline is no longer recommended. N-acetylcysteine has been studied as an adjunct.
4. Alcohol Use Disorder Pharmacotherapy in Liver Disease
This is the APRN's decision and a recurring exam scenario.
| Medication | Compensated liver disease | Significant hepatic impairment / cirrhosis |
|---|---|---|
| Naltrexone | Reasonable with monitoring; the old blanket contraindication has softened, and hepatotoxicity was seen with doses far above 50 mg | Generally avoided in acute hepatitis and decompensated cirrhosis |
| Acamprosate | Effective; no hepatic metabolism | Preferred when hepatic clearance is impaired, provided creatinine clearance exceeds 30 mL/min; contraindicated below 30 mL/min |
| Disulfiram | Avoid | Contraindicated — hepatotoxic and dangerous in advanced disease |
| Baclofen | Off-label option | The agent with the most randomized data specifically in cirrhosis; renally cleared |
| Topiramate / gabapentin | Off-label options | Use caution; both can worsen encephalopathy-like cognitive effects |
5. Transplant and the Abstinence Question
The historical "six-month rule" — six months of documented abstinence before listing — has been substantially revised. Multiple transplant centers now perform early liver transplantation for carefully selected patients with severe alcohol-associated hepatitis who do not respond to medical therapy, using psychosocial assessment rather than a fixed abstinence interval. The APRN's contribution is the psychosocial and addiction assessment: insight, support system, prior treatment response, co-occurring disorders, and a concrete relapse-prevention plan including medication for alcohol use disorder. A blanket statement that a patient "must be sober six months" is outdated and, on the exam, wrong.
A patient with heavy daily alcohol use presents with jaundice. AST is 240 IU/L, ALT is 95 IU/L, total bilirubin is 9.8 mg/dL, and the white cell count is elevated. Which interpretation is correct?
A patient with decompensated alcohol-associated cirrhosis and a creatinine clearance of 62 mL/min wants medication to help maintain abstinence. Which choice is most appropriate?
A patient with severe alcohol-associated hepatitis was started on prednisolone 40 mg daily. On day 7 the Lille score is 0.62. What does this indicate?